Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (3y) (2020 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | 144.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.46% |
| Mar 31, 2026 | 139.66% |
| Dec 31, 2025 | 88.10% |
| Sep 30, 2025 | -18.43% |
| Jun 30, 2025 | 77.48% |
| Mar 31, 2025 | 37.61% |
| Dec 31, 2024 | 44.13% |
| Sep 30, 2024 | 57.19% |
| Jun 30, 2024 | 28.73% |
| Mar 31, 2024 | 28.05% |
| Dec 31, 2023 | 28.16% |
| Sep 30, 2023 | 35.63% |
| Jun 30, 2023 | 49.59% |
| Mar 31, 2023 | 48.80% |
| Dec 31, 2022 | 21.76% |
| Sep 30, 2022 | 60.31% |
| Jun 30, 2022 | 42.74% |
| Mar 31, 2022 | 16.49% |
| Dec 31, 2021 | 11.92% |
| Sep 30, 2021 | -11.65% |